Quinidine是一种从金鸡纳树皮中提取的Ia类抗心律失常药物,属于K+通道阻滞剂(IC50=19.9μM),可抑制细胞色素P450db(cytochrome P450db)活性。
Cas No.:56-54-2
Sample solution is provided at 25 µL, 10mM.
Quinidine is a class Ia antiarrhythmic agent extracted from cinchona bark, which functions as a K⁺ channel blocker (IC₅₀=19.9µM) and inhibits cytochrome P450db activity. Quinidine reduces automaticity, slows conduction velocity, and prolongs the effective refractory period by inhibiting sodium channels on the cardiomyocyte membrane. Quinidine produces vasodilatory effects through anticholinergic action and α-receptor blockade. Quinidine can be used in research related to atrial fibrillation, atrial flutter, and supraventricular tachycardia[1-4].
In vitro, Quinidine (300µM) was used to treat C6 glioma cells for 48 hours. Quinidine significantly reduced cell proliferation, arrested the cell cycle in the G0/G1 phase, and decreased ornithine decarboxylase (ODC) activity and putrescine concentration[5]. Quinidine (90µM) was used to treat MCF-7 human breast cancer cells for 24–96 hours. Quinidine reduced the expression of the cell cycle marker Ki67 antigen and induced apoptosis and necrosis[6].
In vivo, Quinidine (2.075mg/100g; single dose) was administered intraperitoneally to Swiss mice immediately after Isoproterenol hydrochloride injection. Quinidine significantly reduced the Isoproterenol hydrochloride-induced elevation in serum glutamic-oxaloacetic transaminase (SGOT) levels and cardiac tissue lipid peroxidation, while modulating cardiac antioxidant enzyme activity and counteracting Isoproterenol hydrochloride-induced myocardial ischemic injury[7]. Quinidine (30mg/kg) was administered as a single intraperitoneal injection to NMRl male mice. Quinidine significantly increased the seizure threshold for pentylenetetrazole (PTZ)-induced tonic hind limb extension (THE)[8].
References:
[1] Grace AA, Camm AJ. Quinidine. N Engl J Med. 1998 Jan 1;338(1):35-45.
[2] Alloway JA, Salata MP. Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum. 1995 Apr;24(5):315-22.
[3] Malik C, Ghosh S. Quinidine partially blocks mitochondrial voltage-dependent anion channel (VDAC). Eur Biophys J. 2020 Mar;49(2):193-205.
[4] Yoshitomi S, Takahashi Y, Yamaguchi T, et al. Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutations. Epileptic Disord. 2019 Feb 1;21(1):48-54.
[5] Weiger TM, Colombatto S, Kainz V, et al. Potassium channel blockers quinidine and caesium halt cell proliferation in C6 glioma cells via a polyamine-dependent mechanism. Biochem Soc Trans. 2007 Apr;35(Pt 2):391-5.
[6] Wang S, Melkoumian Z, Woodfork KA, et al. Evidence for an early G1 ionic event necessary for cell cycle progression and survival in the MCF-7 human breast carcinoma cell line. J Cell Physiol. 1998 Sep;176(3):456-64.
[7] Chattopadhyay A, Biswas S, Bandyopadhyay D, et al. Effect of isoproterenol on lipid peroxidation and antioxidant enzymes of myocardial tissue of mice and protection by quinidine. Mol Cell Biochem. 2003 Mar;245(1-2):43-9.
[8] Jamali H, Heydari A. Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice. Neurosci Lett. 2020 Jun 11;729:134988.
Quinidine是一种从金鸡纳树皮中提取的Ia类抗心律失常药物,属于K+通道阻滞剂(IC50=19.9μM),可抑制细胞色素P450db(cytochrome P450db)活性。Quinidine可通过抑制心肌细胞膜上的钠离子通道来降低自律性、减慢传导速度和延长有效不应期。Quinidine通过抗胆碱作用和阻断α受体以产生血管扩张效应。Quinidine可用于心房颤动、心房扑动及室上性心动过速等相关研究[1-4]。
在体外,Quinidine(300μM)处理C6胶质瘤细胞48小时。Quinidine显著减少细胞增殖,阻滞细胞周期在G0/G1期,同时降低鸟氨酸脱羧酶(ODC)活性和腐胺浓度[5]。Quinidine(90μM)处理MCF-7人乳腺癌细胞24-96小时。Quinidine会降低细胞周期标志物Ki67抗原的表达,引发细胞凋亡与坏死[6]。
在体内,在Isoproterenol hydrochloride注射后,Quinidine(2.075mg/100g;单次)立即腹腔注射给予Swiss小鼠。Quinidine显著降低了由Isoproterenol hydrochloride素诱导的血清谷草转氨酶(SGOT)水平升高和心脏组织脂质过氧化,同时调节心脏抗氧化酶活性,并对抗Isoproterenol hydrochloride诱导的心肌缺血损伤[7]。Quinidine(30mg/kg)单次腹腔注射处理NMRI雄性小鼠。Quinidine显著增加了由戊四唑(PTZ)诱导的强直性后肢伸展(THE)的惊厥阈值[8]。
| Cell experiment [1]: | |
Cell lines | C6 glioma cells (rat glioma cell line) |
Preparation Method | C6 glioma cells were maintained in Ham's F-10 medium supplemented with 9% fetal calf serum (FCS) and 1% penicillin/streptomycin at 37°C, 5% CO₂, and 90% humidity. C6 glioma cells were treated with Quinidine at 300µM for 48 hours. |
Reaction Conditions | 300µM; 48h |
Applications | Quinidine significantly reduced cell proliferation with an EC₅₀ of 112µM. Quinidine depolarized the cell membrane by approximately +16.53mV, arrested cells in the G0/G1 phase of the cell cycle, and reduced S-phase. Quinidine decreased intracellular putrescine concentration below detection levels, inhibited ornithine decarboxylase (ODC) activity, reduced polyamine (putrescine) uptake, diminished mitochondrial activity, and increased lactate dehydrogenase (LDH) release. |
| Animal experiment [2]: | |
Animal models | NMRI male mice |
Preparation Method | Mice were intraperitoneally administered a single dose of Quinidine (30mg/kg). Thirty minutes after Quinidine administration, seizures were induced by intravenous infusion of pentylenetetrazole (PTZ) via the tail vein. |
Dosage form | 30mg/kg; i.p.; single injection |
Applications | Quinidine was ineffective in changing the seizure threshold for the onset of myoclonic (MC) twitch. Quinidine significantly increased the threshold dose for the onset of tonic hind limb extension (THE) compared to the saline-treated control group. |
References: | |
| Cas No. | 56-54-2 | SDF | |
| 别名 | 奎尼丁 | ||
| 化学名 | (R)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5S)-5-vinylquinuclidin-2-yl)methanol | ||
| Canonical SMILES | O[C@H](C(C1=C2)=CC=NC1=CC=C2OC)[C@@H]3[N@@]4C[C@@H](C=C)[C@@H](CC4)C3 | ||
| 分子式 | C20H24N2O2 | 分子量 | 324.42 |
| 溶解度 | ≥ 11.95mg/mL in DMSO | 储存条件 | 4°C, protect from light, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0824 mL | 15.4121 mL | 30.8242 mL |
| 5 mM | 616.5 μL | 3.0824 mL | 6.1648 mL |
| 10 mM | 308.2 μL | 1.5412 mL | 3.0824 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















